Is it time to screen for multiple myeloma?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.Haematologica · 2026
   Article
2. Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention.Cancer research communications · 2026
   Article
3. MGUS prevalence among active-duty military personnel.Blood cancer journal · 2026
   Article
4. Engineering TCR-directed T-cells for the treatment of multiple myeloma.Frontiers in immunology · 2026
   Review
5. Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study.Blood cancer journal · 2025
   Article
6. Genetic, epigenetic, and molecular determinants of multiple myeloma and precursor plasma cell disorders: a pathophysiological overview.Medical oncology (Northwood, London, England) · 2025
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.